tiprankstipranks
Advertisement
Advertisement

URGN Stock Latest News

UroGen Pharma price target raised to $60 from $50 at Oppenheimer
The FlyUroGen Pharma price target raised to $60 from $50 at Oppenheimer
1d ago
URGN
UroGen Pharma price target raised to $58 from $42 at Guggenheim
PremiumThe Fly
UroGen Pharma price target raised to $58 from $42 at Guggenheim
1d ago
URGN
UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright
PremiumThe Fly
UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright
1d ago
URGN
UroGen Pharma price target raised to $60 from $50 at TD Cowen
PremiumThe Fly
UroGen Pharma price target raised to $60 from $50 at TD Cowen
2d ago
URGN
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
PremiumRatings
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
17d ago
URGN
UroGen Pharma price target raised to $42 from $32 at Guggenheim
PremiumThe FlyUroGen Pharma price target raised to $42 from $32 at Guggenheim
17d ago
URGN
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
Premium
The Fly
UroGen Pharma price target raised to $50 from $40 at Oppenheimer
22d ago
URGN
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Premium
The Fly
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
23d ago
URGN
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
PremiumThe Fly
UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103
23d ago
URGN
UroGen Pharma announces FDA clearance for UGN-501 IND application
PremiumThe Fly
UroGen Pharma announces FDA clearance for UGN-501 IND application
1M ago
URGN
UroGen Shareholders Approve Governance, Compensation and Auditor Changes
PremiumCompany Announcements
UroGen Shareholders Approve Governance, Compensation and Auditor Changes
1M ago
8K
URGN
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
PremiumTipRanks Newswire
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
2M ago
ALMS
NVCT
Bancroft Reiterates Buy on Zusduri Upside and Pipeline Strength, Maintains $35 Price Target
PremiumRatingsBancroft Reiterates Buy on Zusduri Upside and Pipeline Strength, Maintains $35 Price Target
2M ago
URGN
UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
Premium
Ratings
UroGen Buy Rating Reiterated as Teva Settlement Extends JELMYTO Exclusivity; $45 Price Target Maintained
2M ago
URGN
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
Premium
Company Announcements
UroGen, Teva Settle Jelmyto Patent Dispute, License Generic
2M ago
8K
URGN
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
PremiumCompany Announcements
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
3M ago
URGN
UroGen Pharma: Buy Rating Reiterated as Strong ZUSDURI Data and UGN-103 Pipeline Support Unchanged $45 Price Target
PremiumRatings
UroGen Pharma: Buy Rating Reiterated as Strong ZUSDURI Data and UGN-103 Pipeline Support Unchanged $45 Price Target
3M ago
URGN
UroGen Pharma reports month results from UTOPIA trial
PremiumThe Fly
UroGen Pharma reports month results from UTOPIA trial
3M ago
URGN
UroGen Pharma presents 36-month ENVISION trial data
PremiumThe Fly
UroGen Pharma presents 36-month ENVISION trial data
3M ago
URGN
UroGen Pharma assumed with a Buy at Ladenburg
PremiumThe FlyUroGen Pharma assumed with a Buy at Ladenburg
3M ago
URGN
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
Premium
The Fly
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
3M ago
URGN
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
Premium
Company Announcements
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
3M ago
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >